Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial.

@article{Hesketh1999EvaluationOD,
  title={Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial.},
  author={Paul Joseph Hesketh and John J. Crowley and Howard A. Burris and Stephen Castles Magdalena Arias Cubas Chulhyo Kim Elsa Kol Williamson and Stanley P. Balcerzak and David M. Peereboom and John Wendall Goodwin and Howard M. Gross and Dennis Moore and Robert B. Livingston and David R. Gandara},
  journal={The cancer journal from Scientific American},
  year={1999},
  volume={5 4},
  pages={237-41}
}
PURPOSE This phase II multi-institutional trial of the Southwest Oncology Group was designed to evaluate the efficacy and toxicity of docetaxel in chemotherapy-naive patients with extensive-stage small cell lung cancer. PATIENTS AND METHODS Forty-seven patients with extensive-stage small cell lung cancer were entered onto the study. Treatment consisted of docetaxel, 100 mg/m2, as a 1-hour intravenous infusion repeated every 21 days, with protocol-specified dose reductions for toxicity… CONTINUE READING